Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Dermatologic 38Thoracic 6CNS 4Other solid neoplasm 3Sarcoma 2Head & Neck 2Gastrointestinal 2Endocrine 2NET 1Myeloid 1Lymphoid 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Advanced Solid Tumors 69Advanced Solid Tumor 58Solid Tumor 50Solid Tumors 42Mesothelioma 40Mesothelioma, Malignant 37Hematopoietic and Lymphatic System Neoplasm 24Solid Tumor, Adult 16Ovarian Neoplasms 13Melanoma 13Malignant Solid Neoplasm 13Carcinoma, Non-Small-Cell Lung 13Sarcoma 11Pancreatic Neoplasms 11Retinoblastoma 10Colorectal Neoplasms 9Stomach Neoplasms 8Lung Neoplasms 8Advanced Malignant Solid Neoplasm 8Solid Tumours 7Small Cell Lung Carcinoma 7Cholangiocarcinoma 7Carcinoma, Renal Cell 7Advanced or Metastatic Solid Tumors 7Kidney Neoplasms 6Carcinoma, Hepatocellular 6Advanced/Metastatic Solid Tumors 6Advanced Malignant Solid Tumor 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 5

Interventions

ruxolitinib 1avelumab 1Pemetrexed 1LY2940680 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Uveal Melanoma × Other solid neoplasm × 90 days × Clear all
NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

iOnctura

Phase 1 Active not recruiting
210 enrolled
DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

NCT04792463 2026-03-09

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

Ohio State University

Recruiting
500 enrolled
DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Uveal Melanoma, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Cholangiocarcinoma

NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Endeavor Biomedicines, Inc.

Phase 2 Completed
20 enrolled
CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡